Introduction
Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant condition with a risk of malignant conversion.
Patients and methods
With the aim to estimate the cumulative risk MGUS progression to hematologic malignancies, we analyzed a nationwide population‐based cohort of 1887 MGUS patients from the Czech Registry of Monoclonal Gammopathies (RMG) between 2007 and 2013.
Results
During the follow‐up period (median 4 years; range 0.6‐34.8), progression to hematologic malignancies was observed in 8.6% (162 of 1887) of patients. Factors associated with progression were as follows: M‐protein concentration ≥1.5 g/dL, pathological sFLC (<0.26 or >1.65) ratio, bone marrow plasma cells (BMPCs) in cytology >5%, immunoparesis, age ≥69 years, and the level of serum hemoglobin at baseline <12.0 g/dL. Combining these factors, we propose a new risk model (CMG model). The risk of progression at 10 years was 1.6%, 16.9%, 22.9%, 39.4%, and 52.3%, respectively, if 0 (reference group), one, two, three, or four to five risk factors are present (P<.001) with HR 63 times higher compared to the reference MGUS group.
Conclusion
The new CMG model was established with an advantage for better identification of MGUS patients at low risk.